Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
Barbara Błaszczyk1,2, Stanisław J Czuczwar3,41Department of Neurology, Neuropsychiatric Hospital, Kielce, Poland; 2Faculty of Health Sciences, High School of Economics and Law, Kielce, Poland; 3Department of Pathophysiology, Medical University, Lublin, Poland; 4Department of Physiopathology, Institu...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d3bf1a42e72c4b09a8bb482a3709abbd |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d3bf1a42e72c4b09a8bb482a3709abbd |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d3bf1a42e72c4b09a8bb482a3709abbd2021-12-02T04:58:34ZEfficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients1176-63281178-2021https://doaj.org/article/d3bf1a42e72c4b09a8bb482a3709abbd2010-04-01T00:00:00Zhttp://www.dovepress.com/efficacy-safety-and-potential-of-extended-release-lamotrigine-in-the-t-a4296https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Barbara Błaszczyk1,2, Stanisław J Czuczwar3,41Department of Neurology, Neuropsychiatric Hospital, Kielce, Poland; 2Faculty of Health Sciences, High School of Economics and Law, Kielce, Poland; 3Department of Pathophysiology, Medical University, Lublin, Poland; 4Department of Physiopathology, Institute of Agricultural Medicine, Lublin, PolandAbstract: Epilepsy is a frequent, chronic disease demanding long-term medication with antiepileptic drugs (AEDs). When slow release formulations of AEDs are used the chance of compliance and control of seizures is increased. Lamotrigine (LTG) is a broad spectrum antiepileptic drug (AED), effective against both generalized and partial seizures. Its immediate-release formulation (LTG-IR) requires twice-daily dosing. In contrast, an extended-release formulation (LTG-XR) may be given once daily, providing a flatter dose-concentration curve with apparently lower maximum serum levels. Simplified dosing positively affects compliance and LTG-XR has a similar profile of efficacy and tolerability to LTG-IR. Rashes, including Stevens–Johnson syndrome, are the most serious adverse effect impacting 0.8% of pediatric patients. Thus, LTG-XR should be discontinued upon the appearance of rash.Keywords: epilepsy, antiepileptic drugs, extended-release, lamotrigine, adverse reactions, tolerability, pharmacokinetics Barbara BłaszczykStanisław J CzuczwarDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 145-150 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Barbara Błaszczyk Stanisław J Czuczwar Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients |
| description |
Barbara Błaszczyk1,2, Stanisław J Czuczwar3,41Department of Neurology, Neuropsychiatric Hospital, Kielce, Poland; 2Faculty of Health Sciences, High School of Economics and Law, Kielce, Poland; 3Department of Pathophysiology, Medical University, Lublin, Poland; 4Department of Physiopathology, Institute of Agricultural Medicine, Lublin, PolandAbstract: Epilepsy is a frequent, chronic disease demanding long-term medication with antiepileptic drugs (AEDs). When slow release formulations of AEDs are used the chance of compliance and control of seizures is increased. Lamotrigine (LTG) is a broad spectrum antiepileptic drug (AED), effective against both generalized and partial seizures. Its immediate-release formulation (LTG-IR) requires twice-daily dosing. In contrast, an extended-release formulation (LTG-XR) may be given once daily, providing a flatter dose-concentration curve with apparently lower maximum serum levels. Simplified dosing positively affects compliance and LTG-XR has a similar profile of efficacy and tolerability to LTG-IR. Rashes, including Stevens–Johnson syndrome, are the most serious adverse effect impacting 0.8% of pediatric patients. Thus, LTG-XR should be discontinued upon the appearance of rash.Keywords: epilepsy, antiepileptic drugs, extended-release, lamotrigine, adverse reactions, tolerability, pharmacokinetics |
| format |
article |
| author |
Barbara Błaszczyk Stanisław J Czuczwar |
| author_facet |
Barbara Błaszczyk Stanisław J Czuczwar |
| author_sort |
Barbara Błaszczyk |
| title |
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients |
| title_short |
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients |
| title_full |
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients |
| title_fullStr |
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients |
| title_full_unstemmed |
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients |
| title_sort |
efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/d3bf1a42e72c4b09a8bb482a3709abbd |
| work_keys_str_mv |
AT barbarabłaszczyk efficacysafetyandpotentialofextendedreleaselamotrigineinthetreatmentofepilepticpatients AT stanisławjczuczwar efficacysafetyandpotentialofextendedreleaselamotrigineinthetreatmentofepilepticpatients |
| _version_ |
1718400981119533056 |